Satyam Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
- Paid Up Capital ₹ 1.50 Cr
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 2.67 Cr
- Revenue Growth -70.54%
- Profit Growth -68.38%
- Ebitda -11.47%
- Net Worth 0.20%
- Total Assets -7.46%
About Satyam Drugs
Satyam Drugs Private Limited (SDPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 12 October 2015 (Nine years and four months 17 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹2.67 Cr.
Raj Garg and Lokesh Kumar serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909DL2015PTC286345
- Company No.
286345
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Oct 2015
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Satyam Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raj Garg  | Director | 12-Oct-2015 | Current |
| Lokesh Kumar | Director | 24-Nov-2021 | Current |
Financial Performance of Satyam Drugs.
Satyam Drugs Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 70.54% decrease. The company also saw a substantial fall in profitability, with a 68.38% decrease in profit. The company's net worth moved up by a moderate rise of 0.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Satyam Drugs?
In 2022, Satyam Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Meditronics Healthcare Solutions Private LimitedLokesh Kumar is a mutual person
Charges (Loans)
₹2.67 Cr
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 2.67 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Aug 2017 | Hdfc Bank Limited | ₹2.67 Cr | Open |
How Many Employees Work at Satyam Drugs?
Unlock and access historical data on people associated with Satyam Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Satyam Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Satyam Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
